Glucagon Monoclonal Antibody (ICACLS), eBioscience™, Invitrogen™

Description

• Description: This ICACLS monoclonal antibody reacts with human, mouse, and rat glucagon
• Glucagon is a peptide hormone secreted by the pancreatic alpha cells found within the islets of Langerhans
• Glucagon functions as an antagonist to insulin and homeostatic regulation of blood glucose levels are maintained by the critical balance between these two hormones
• Glucagon acts in the liver to convert glycogen to glucose by promoting gluconeogenesis and glycogenolysis
• Secretion of glucagon is stimulated by hypoglycemia, epinephrine, acetylcholine, and cholecystokinin, while secretion is inhibited by insulin and somatostatin
• Abnormally high levels of glucagon are found in pancreatic tumors
• Applications Reported: This ICACLS antibody has been reported for use in immunohistochemical staining, and immunohistochemical staining of formalin-fixed paraffin embedded tissue sections
• Applications Tested: This ICACLS antibody has been tested by immunohistochemistry of formalin-fixed paraffin embedded human tissue using low pH antigen retrieval and can be used at less than or equal to 0.1 μg/mL
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• Glucagon is a 29-residue polypeptide hormone (MW 3482), produced in the pancreas
• A related hormone, enteroglucagon (or oxyntomodulin), which is produced in the mucosa of the small and large intestine, consists of the 29 amino acid sequence of pancreatic glucagon extended by 8 additional residues at the C-terminus
• The biological activities of pancreatic glucagon include glycogenolysis, lipolysis, gluconeogenesis, and ketogensis, which are antagonistic effects to those of insulin action, thus leading to increased blood glucose levels
• Immunocytochemical studies have revealed the presence of pancreatic glucagon inside the A or alpha cells, which constitute 15-20% of the islet cell population
• These cells are located preferentially at the periphery of the human pancreatic islets
• Pathological manifestations of the glucagon-type peptide residue almost exclusively with the exsistence of tumors or glucagonomas, as no states of glucagon-cell deficiency or hyperplasia have been identified
• Glucagon-specific antibodies would prove useful as a cell and tumor markers applying immunohistochemical techniques, and as an analytical tool in qualification of the hormone.